Anandappa, Gayathri <br/><br/>
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  07 2019 
 - 3830-3838 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-18-3769  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Colorectal Neoplasms--diagnosis<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Gene Expression<br/>Humans<br/>Immunohistochemistry<br/>In Situ Hybridization<br/>Male<br/>MicroRNAs--genetics<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Prognosis<br/>Retreatment<br/>Tomography, X-Ray Computed<br/>Treatment Outcome